Eckert & Ziegler BEBIG: Half Year Results 2013 Published

Eckert & Ziegler BEBIG: Half Year Results 2013 Published

ID: 287994

(Thomson Reuters ONE) -


Regulated information

Seneffe - Belgium, August 15, 2013, Eckert & Ziegler BEBIG (Euronext: EZBG;
Reuters: EZBG.BR; Bloomberg: EZBG:BB) has announced today its financial results
for the first half of 2013.


The report including the milestones and a selection of consolidated key figures
of the first half of 2013 can be downloaded at:


www.bebig.eu > Investor Relations > Financial Reports

Eckert & Ziegler BEBIG
...Contributing to saving lives!


Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.

Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India and in Brazil. Eckert &
Ziegler BEBIG has also established a worldwide network of distributors and
agents to support its product line.

The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.

Eckert & Ziegler BEBIG employs about 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).

Contact:
Eckert & Ziegler BEBIG s.a.
Investor Relations
Tel: +32 (0) 64 520 808
E-mail: ir(at)bebig.eu



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.





Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1723070]




Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Novartis vaccine Bexsero® approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis DGAP-News: Nordex raises full-year guidance for 2013 following a strong first half
Bereitgestellt von Benutzer: hugin
Datum: 15.08.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 287994
Anzahl Zeichen: 2178

contact information:
Town:

Seneffe



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 221 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: Half Year Results 2013 Published"
steht unter der journalistisch-redaktionellen Verantwortung von

Eckert & Ziegler BEBIG (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Eckert & Ziegler BEBIG



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z